RT Journal Article SR Electronic T1 Activation of the liver X receptors alters CD4+ T cell membrane lipids and signalling through direct regulation of glycosphingolipid synthesis JF bioRxiv FD Cold Spring Harbor Laboratory SP 721050 DO 10.1101/721050 A1 Kirsty E Waddington A1 George A Robinson A1 Marsilio Adriani A1 Beatriz Rubio-Cuesta A1 Eden Chrifi-Alaoui A1 Sara Andreone A1 Kok-Siong Poon A1 Iveta Ivanova A1 Lucia Martin-Gutierrez A1 Dylan M Owen A1 Petra Nytrova A1 Eva Kubala Havrdova A1 Rachel Farrell A1 Elizabeth C Jury A1 Inés Pineda-Torra YR 2019 UL http://biorxiv.org/content/early/2019/08/23/721050.abstract AB Liver X Receptors (LXRs) are important transcriptional regulators of intracellular cholesterol, fatty acid, and phospholipid levels. LXRs can dampen inflammation in macrophages by promoting cholesterol efflux and altering plasma membrane lipid rafts; microdomains enriched for cholesterol and glycosphingolipids that regulate immune-cell signalling. However, little is known about the impact of LXR activators on T cell plasma membrane lipid rafts, which are critical for T-cell antigen receptor (TCR) signalling. Here we show that the LXR synthetic agonist GW3965 significantly increases glycosphingolipid levels and reduces cholesterol and lipid order (stability) in the plasma membrane of human CD4+ T cells. Moreover, the GSL biosynthesis enzyme UGCG was identified as a novel direct target of LXR activation. Importantly, LXR-mediated changes in T cell lipid composition were associated with altered spatiotemporal distribution of lipids and signalling molecules at the immune synapse. Crucially, LXR activation altered the kinetics of proximal TCR-signalling events in activated T cells, reduced T cell proliferation and enhanced the production of IL-2 and IL-4. Thus, LXR activation influences T cell function via alteration of the plasma membrane lipid profile. Finally, the expression of UGCG and other LXR-regulated genes and lipids was significantly dysregulated in T-cells isolated from people with multiple sclerosis. Overall, a novel action of LXR has been characterised that involves modulation of lipid raft-associated cholesterol and glycosphingolipids in CD4+ T-cells, which could be of therapeutic relevance in multiple sclerosis.